Scrip Asia 100 - S*BIO sticks to the book on its road to market
This article was originally published in Scrip
Executive Summary
Thanks to healthy income from licensing partners, S*BIO is in the enviable position of being able to plan carefully both its strategy for internal R&D and future financing. The attractions of Singapore have also helped S*BIO to recruit a surprisingly international workforce, Dr Jan-Anders Karlsson, the bioventure's CEO, tells Ian Haydock.